Clinical Trials
160 trialsA Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors
GlaxoSmithKline
A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
Blueprint Medicines Corporation
DEL-LIVER
Delcath Systems Inc.
KANDLELIT-012
Merck Sharp & Dohme LLC
CEA+RC-BCG
Medicine Invention Design, Inc
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-8989 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutations
Shenzhen Ionova Life Sciences Co., Ltd.
AZUR-1
GlaxoSmithKline
EVEREST-2
A2 Biotherapeutics Inc.
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.
Pfizer
AMPLIFY-7P
Elicio Therapeutics
Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors
Revolution Medicines, Inc.
COMPANION-003
Compass Therapeutics
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
ModeX Therapeutics, An OPKO Health Company
A Study of PF-08046052/SGN-EGFRd2 in Advanced Solid Tumors
Seagen Inc.
KRYSTAL-10
Mirati Therapeutics Inc.
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Revolution Medicines, Inc.
A Study of Atezolizumab With or Without Tiragolumab Following Neoadjuvant Chemoradiotherapy in Participants With Locally Advanced Rectal Cancer
Hoffmann-La Roche
A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.
Pfizer
SEAMARK
Pfizer
SECURE
Medtronic - MITG
First-in-Human Study of ATX-559, an Oral Inhibitor of DHX9, in Patients With Advanced or Metastatic Solid Tumors, and Molecularly Defined Cancers
Accent Therapeutics
ColoSealâ„¢ ICD System Anastomotic Protection Pivotal Study
Averto Medical, Inc.
SYLVER
GlaxoSmithKline
SCORE
Natera, Inc.
INJECTABL-3
Immunophotonics, Inc.
A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers
Novartis
VARTUTRACE
Var2 Pharmaceuticals
PREEMPT CRC
Freenome Holdings Inc.
A Study of Select Drug Combinations in Adult Patients With Advanced/Metastatic BRAF V600 Colorectal Cancer
Novartis
China AZUR-1
GlaxoSmithKline
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Massive Bio, Inc.
Efficacy and Safety of the CG-100 Intraluminal Bypass Device
Colospan Ltd.
CEA-Targeted CAR-T Therapy in CEA-Positive Advanced Solid Tumors
Chongqing Precision Biotech Co., Ltd
xDRIVE in Metastatic Colorectal Cancer
First Ascent Biomedical Inc.
DENALI-1
A2 Biotherapeutics Inc.
AMPLIFY-201
Elicio Therapeutics
ORACLE
Guardant Health, Inc.
A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer
Pfizer
SAFE-2
SafeHeal Inc
Bovine Reinforcement in Stomach, Colorectal and Lung Operation
Shanghai Cingularbio Co. Ltd
Tempus Priority Study: A Pan-tumor Observational Study
Tempus AI
MINIGO
Qufora A/S
Live Biotherapeutic Product GB104 Phase 1 Study in Colorectal Cancer
GILongevity
KISIMA-01
Amal Therapeutics
Intestinal Microbiome, Oral Microbiome, and Whole Blood Transcriptome Analyses in Gastrointestinal Malignancies
Viome
ROOT
Taproot Health
Validation of a Molecular Signature for Early Detection of Colorectal Cancer
ADVANCED MARKER DISCOVERY S.L.
A Multi-Center, Open-Label Study of Fruquintinib in Solid Tumors and Colorectal, and Breast Cancers
Hutchmed
ctDNA Monitoring to Predict the Efficacy of TNT for Rectal Cancer
Gene Solutions